MS Sparsha
Dr Rustom Jal Vakil helped bring an ancient Indian remedy for high blood pressure to the attention of modern medicine, exposing a remarkable gap between scientific evidence and its acceptance.
In 1949, the medical world was still struggling to find effective ways to control high blood pressure. Yet, in India, doctors had already been prescribing a remedy derived from a humble medicinal plant for years. Its name was Rauwolfia serpentina, popularly known as sarpagandha. The man who helped carry its potential from Indian medical practice to the international scientific community was Dr Rustom Jal Vakil, a pioneering cardiologist whose contribution deserves a much wider place in the history of medicine.
The story is not merely about a plant or a physician. It is about indigenous knowledge, scientific perseverance and the extraordinary consequences of overlooking discoveries simply because they originate outside the dominant centres of medical research.
An ancient remedy, a modern discovery
Sarpagandha had been used in traditional Indian medicine for centuries. Its potential, however, did not remain confined to traditional practice. Indian researchers began publishing modern scientific observations on the plant as early as 1931. These investigations explored its medicinal properties, including its possible role in treating hypertension and certain mental disorders.
By the late 1940s, Rauwolfia preparations had gained considerable acceptance among Indian physicians. According to historical accounts, the medicine was being prescribed widely, and commercial demand had grown substantially. The knowledge was not secret, nor was it inaccessible. Indian medical journals carried reports that were available in scientific libraries around the world.
Yet, Western medicine largely failed to recognise the significance of this growing body of evidence.
The contrast was striking: Indian doctors were using the remedy, Indian researchers were studying it, and patients were receiving it, while much of the international medical establishment continued to pursue other avenues for controlling high blood pressure.
It was against this background that Dr Vakil undertook work that would change the course of the story.
Ten years of painstaking research
Dr Vakil had returned to India in 1938 after obtaining his medical degree from the University of London. He devoted himself to the treatment of heart ailments at a time when cardiology was still developing as a distinct speciality in the country.
Rather than dismissing an indigenous remedy or accepting its reputation without scrutiny, he approached it as a clinician and researcher. He systematically examined his own clinical experience over approximately a decade and brought together observations from other practising physicians.
His landmark paper, A Clinical Trial of Rauwolfia Serpentina in Essential Hypertension, appeared in the British Heart Journal in October 1949. It presented clinical evidence on the plant’s blood-pressure-lowering properties and helped introduce its therapeutic potential to a much wider international audience.
Photo
Caption: Vakil (left) receiving the American College of Cardiology fellowship certificate from the American consul in Bombay
The importance of his work lay not simply in advocating a traditional remedy, but in documenting its effects in a form that the international medical community could examine and debate.
Dr Vakil also sought the experience of fellow practitioners. In his historical review, he drew on responses from approximately 50 physicians in India who had used Rauwolfia for hypertension. The overwhelming preference expressed by these doctors reinforced the case for further scientific investigation.
His work helped transform what had largely been an Indian clinical experience into a subject of serious international research.
The evidence that could not be ignored
The clinical observations reported by Dr Vakil were significant. In a study involving 50 patients, approximately 85 per cent showed a reduction in systolic blood pressure after four weeks of treatment, with an average fall of about 21 mmHg, according to the account of the trial.
These findings were not the final word on the medicine’s efficacy or safety. They were, however, compelling enough to encourage further investigation into Rauwolfia and its active constituents.
The response was rapid. Within the following five years, more than 100 papers on the subject appeared internationally, reflecting the surge of scientific interest generated by the growing evidence.
In 1952, researchers isolated reserpine, an important active alkaloid found in Rauwolfia. It subsequently attracted attention for its blood-pressure-lowering and tranquillising effects. By 1954, reserpine was being used in psychiatric treatment, opening another important chapter in the history of pharmacology.
An Indian medicinal plant had thus helped stimulate research that extended well beyond the treatment of hypertension.
An international honour—and an uncomfortable question
In 1957, Dr Vakil received the prestigious Albert Lasker Award for Clinical Medical Research for his systematic studies on Rauwolfia in hypertension. He was recognised internationally for helping bridge the divide between Indian medical experience and Western medicine.
The award citation contained an observation that remains relevant even today. Referring to the long delay in recognising the significance of Rauwolfia, it described the episode as “a block in medical communication that, in retrospect, seems hard to understand”.
That sentence is perhaps the most powerful part of this story.
The evidence had existed. The research had been published. The medicine had been used by physicians in India. Yet international recognition came only after a determined doctor assembled the findings, presented them in a widely read journal and made it difficult for the wider medical community to overlook them.
The episode raises a timeless question: how many potentially valuable discoveries have been delayed because the scientific world failed to pay sufficient attention to evidence emerging beyond its established centres of influence?
A legacy beyond an award
Dr Vakil’s contribution extended beyond Rauwolfia. He helped establish cardiology as an important speciality in India and contributed to cardiovascular research and medical education. His achievements were also recognised by the Government of India, which awarded him the Padma Bhushan in 1958.
Today, medical science has advanced enormously, and the treatment of hypertension relies on a range of medicines selected according to individual clinical needs. Rauwolfia and reserpine are important parts of that history, rather than substitutes for modern, medically supervised treatment.
But the historical lesson remains powerful. Scientific progress depends not only on making discoveries, but also on examining evidence wherever it originates, communicating it effectively and remaining open to knowledge that challenges prevailing assumptions.
Dr Rustom Jal Vakil did precisely that. He took an Indian medicinal tradition seriously enough to investigate it rigorously and presented his findings with the persistence of a scientist who believed that evidence deserved to be heard.
His greatest achievement was not simply drawing attention to a medicinal plant. It was helping the world recognise that valuable medical knowledge need not originate in the laboratories and institutions it already considers authoritative.
That is why Dr Rustom Jal Vakil belongs among India’s unsung heroes—not merely as a pioneering cardiologist, but as a reminder that the world can lose precious years when it overlooks the discoveries of others.
